Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report

Acta Derm Venereol. 2023 Aug 1:103:adv9646. doi: 10.2340/actadv.v103.9646.

Authors

Han Seul Kim¹, Ji Eun Kwon², Young Joon Park³

Affiliations

¹ Department of Dermatology, Ajou University School of Medicine, Suwon, Korea.
² Department of Pathology, Ajou University School of Medicine, Suwon, Korea.
³ Department of Dermatology, Ajou University School of Medicine, Suwon, Korea. aro@ajou.ac.kr.

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Bevacizumab / adverse effects
Humans
Pyoderma Gangrenosum* / chemically induced
Pyoderma Gangrenosum* / diagnosis
Pyoderma Gangrenosum* / drug therapy

Substances

atezolizumab
Bevacizumab
baricitinib
Antibodies, Monoclonal, Humanized